Motonobu Osada
Overview
Explore the profile of Motonobu Osada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1073
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oh D, Ikeda M, Lee C, Rojas C, Hsu C, Kim J, et al.
Hepatology
. 2024 Jun;
81(3):823-836.
PMID: 38875119
Background And Aims: We compared the safety and efficacy of bintrafusp alfa (BA) in combination with gemcitabine+cisplatin (GemCis), to those of GemCis alone, in patients with biliary tract cancer. Approach...
2.
Vugmeyster Y, Grisic A, Wilkins J, Loos A, Hallwachs R, Osada M, et al.
Cancer Chemother Pharmacol
. 2022 Sep;
90(4):369-379.
PMID: 36066618
Purpose: Bintrafusp alfa (BA) is a bifunctional fusion protein composed of the extracellular domain of the transforming growth factor-β (TGF-β) receptor II fused to a human immunoglobulin G1 antibody blocking...
3.
Lin C, Doi T, Muro K, Hou M, Esaki T, Hara H, et al.
Target Oncol
. 2021 Apr;
16(4):447-459.
PMID: 33840050
Background: Patients with esophageal squamous cell carcinoma (SCC) have limited treatment options. Blocking transforming growth factor-β (TGFβ), which can be overexpressed in these tumors, may enhance responses to programmed cell...
4.
Yoo C, Oh D, Choi H, Kudo M, Ueno M, Kondo S, et al.
J Immunother Cancer
. 2020 May;
8(1).
PMID: 32461347
Background: Patients with biliary tract cancer (BTC) have poor prognosis with few treatment options. Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of the transforming growth...
5.
Kang Y, Bang Y, Kondo S, Chung H, Muro K, Dussault I, et al.
Clin Cancer Res
. 2020 Apr;
26(13):3202-3210.
PMID: 32299818
Purpose: Patients with advanced gastric/gastroesophageal junction cancer (GC/GEJC) have limited treatment options after first-line therapy. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of the...
6.
Kim S, Meric-Bernstam F, Kalyan A, Babich A, Liu R, Tanigawa T, et al.
Target Oncol
. 2019 Sep;
14(5):591-601.
PMID: 31502117
Background: Fibroblast growth factor receptor (FGFR) 2 is overexpressed in several tumor types, including triple-negative breast cancer and gastric cancer, both of which have a high unmet medical need. Aprutumab...
7.
Doi T, Fuse N, Yoshino T, Kojima T, Bando H, Miyamoto H, et al.
Cancer Chemother Pharmacol
. 2016 Dec;
79(1):89-98.
PMID: 27915408
Purpose: To evaluate the safety, tolerability, pharmacokinetics, and efficacy of the intravenously administered pan-PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors. Methods: A Phase I open-label...
8.
Tokumaru Y, Yamashita K, Kim M, Park H, Osada M, Mori M, et al.
Int J Cancer
. 2008 May;
123(4):753-9.
PMID: 18512240
PGP9.5 is a controversial molecule from an oncologic point of view. We recently identified frequent methylation of PGP9.5 gene exclusively in primary head and neck squamous cell carcinoma (HNSCC), suggesting...
9.
Park H, Kim M, Yamashita K, Westra W, Carvalho A, Lee J, et al.
Int J Cancer
. 2008 Feb;
122(11):2498-502.
PMID: 18302152
Deleted in Colorectal Cancer (DCC) is a putative tumor suppressor gene, whose loss has been implicated in colorectal tumorigenesis. Decreased or loss of DCC expression has been demonstrated in a...
10.
Yamashita K, Kim M, Park H, Tokumaru Y, Osada M, Inoue H, et al.
Mol Cancer Res
. 2008 Feb;
6(1):31-41.
PMID: 18234960
Promoter DNA hypermethylation with gene silencing is a common feature of human cancer, and cancer-prone methylation is believed to be a landmark of tumor suppressor genes (TSG). Identification of novel...